Evidence map›Paper›PMID 20861920›Full record

Trial reportLeukemia2010

NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951.

E Clappier, S Collette, N Grardel, S Girard, L Suarez, G Brunie, S Kaltenbach, K Yakouben, F Mazingue, A Robert and 13 more

Registry-linked trialAbstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00003728 (The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood), which is not on this map. Cited by 62 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 2 pooled it
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00003728 phase3unknown statusnot on this map

The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood

TypeinterventionalSponsorEuropean Organisation for Research and Treatment of Cancer - EORTCRan1998Enrolled1,500ConditionsLeukemia, LymphomaArmsasparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 127 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. [The role and research progress of NOTCH1 in T-cell acute lymphoblastic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021
    Article
  19. Review
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 11 institutions in 2 countries.

E ClappierDépartement de Génétique, APHP, Hôpital Robert Debré, Université Paris 7-Denis Diderot, Paris, France.
S Collette
N Grardel
S Girard
L Suarez
G Brunie
S Kaltenbach
K Yakouben
F Mazingue
A Robert
P Boutard
D Plantaz
P Rohrlich
P van Vlierberghe
C Preudhomme
J Otten
F Speleman
N Dastugue
S Suciu
Y Benoit
Y Bertrand
H Cavé
EORTC-CLG
Hôpital Robert-Debré · FRGhent University Hospital · BEEuropean Organisation for Research and Treatment of Cancer · BEHôpital Purpan · FRInserm · FRInstitut d’Hématologie et d’Oncologie Pédiatrique · FRUniversité Paris Cité · FRCentre Hospitalier Universitaire de Grenoble · FRHôpital Edouard Herriot · FRHôpital Saint-Jacques · FRUniversitair Ziekenhuis Brussel · BE

Funding

EORTC HEADQUARTERSU10CA011488 · NCI · EUROPEAN ORG/RES/TREATMENT/CANCER · PI LACOMBE, DENIS · 1985 to 2015
$6.6M
NCI NIH HHS 5U10 CA11488-20NCI NIH HHS 5U10 CA11488-21NCI NIH HHS 5U10 CA11488-22NCI NIH HHS 5U10 CA11488-23NCI NIH HHS 5U10 CA11488-24NCI NIH HHS 5U10 CA11488-25NCI NIH HHS 5U10 CA11488-26NCI NIH HHS 5U10 CA11488-27NCI NIH HHS 5U10 CA11488-28NCI NIH HHS 5U10 CA11488-29NCI NIH HHS 5U10 CA11488-30NCI NIH HHS 5U10 CA11488-31NCI NIH HHS 5U10 CA11488-32NCI NIH HHS 5U10 CA11488-33NCI NIH HHS 5U10 CA11488-34NCI NIH HHS 5U10 CA11488-35NCI NIH HHS 5U10 CA11488-36NCI NIH HHS 5U10 CA11488-37NCI NIH HHS 5U10 CA11488-38NCI NIH HHS 5U10 CA11488-39
6 · The paper itself

Abstract

Risk-adjusted treatment stratification in T-cell acute lymphoblastic leukemias (T-ALLs) is currently based only on early response to chemotherapy. We investigated the prognostic implication of hyperactivation of NOTCH pathway resulting from mutations of NOTCH1 or FBXW7 in children with T-ALL enrolled in EORTC-CLG trials. Overall, 80 out of 134 (60%) patients were NOTCH+ (NOTCH1 and/or FBXW7 mutated). Although clinical presentations were not significantly associated with NOTCH status, NOTCH+ patients showed a better early response to chemotherapy as compared with NOTCH- patients, according to the rate of poor pre-phase 'responders' (25% versus 44%; P=0.02) and the incidence of high minimal residual disease (MRD) levels (11% (7/62) versus 32% (10/31); P=0.01) at completion of induction. However, the outcome of NOTCH+ patients was similar to that of NOTCH- patients, with a 5-year event-free survival (EFS) of 73% and 70% (P=0.82), and 5-year overall survival of 82% and 79% (P=0.62), respectively. In patients with high MRD levels, the 5-year EFS rate was 0% (NOTCH+) versus 42% (NOTCH-), whereas in those with low MRD levels, the outcome was similar: 76% (NOTCH+) versus 78% (NOTCH-). The incidence of isolated central nervous system (CNS) relapses was relatively high in NOTCH1+ patients (8.3%), which could be related to a higher propensity of NOTCH+ leukemic blasts to target the CNS.

Indexed as

MutationCell Cycle ProteinsChildDisease-Free SurvivalF-Box ProteinsF-Box-WD Repeat-Containing Protein 7HumansPrecursor T-Cell Lymphoblastic Leukemia-LymphomaProspective StudiesReceptor, Notch1Ubiquitin-Protein LigasesCell Cycle ProteinsF-Box ProteinsF-Box-WD Repeat-Containing Protein 7FBXW7 protein, humanNOTCH1 protein, humanReceptor, Notch1Ubiquitin-Protein Ligases

Identifiers

PMID20861920
OpenAlexW2073345709

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.